Take the patient sample, send it to the laboratory and wait for the test results. It can be a lengthy process at times. Point-of-care tests make it possible for physicians to get faster test results right on the spot. At COMPAMED 2018, the EU-funded "PoC-ID Project" will showcase an ultra-sensitive point-of-care system to diagnose RSV infections.
The innovative ultrasensitive point-of-care system is designed to help speed up the diagnosis of RSV infections, particularly those affecting children.
Respiratory syncytial virus (RSV) is a global common and very contagious virus that infects the respiratory tract. Though it can affect people of all ages, it is one of the most important pathogens of respiratory infections in infants, premature babies and toddlers. Given that infectious diseases are still among the leading causes of death worldwide, point-of-care testing is a popular method of diagnostics. This is the starting point for the "Platform for Ultra-Sensitive Point-of-Care Diagnostics for Infectious Diseases". After all, there is a high demand for rapid and sensitive point-of-care diagnostics that reduce healthcare costs and improve the quality of life at the same time.
The objective of the PoC-ID project is to develop new micro and nano technologies and improve sensing and integration concepts to make miniaturized in vitro diagnostic devices faster and more accurate. Coordinated by the Research Center for Microperipheric Technologies, Research Center for Microperipheric Technologies System Integration & Interconnection Technologies of the Technical University of Berlin, 13 corporate and academic expert teams from seven European countries have partnered up and worked on a PoC prototype for the diagnosis of respiratory syncytial virus infections since mid-2015. What makes this so unique is that the prototype was also developed for use in infants and toddlers, who are particularly susceptible.
Two aspects, one result
The approach: Merging what is already known and available with new aspects. The PoC-ID device combines the detection of both host and pathogen biomarkers in the same sample, leading to a rapid and more accurate diagnosis and prognosis. To accomplish this, innovative biomolecular capture molecules (aptamers) based on RNA oligonucleotides are combined with two new ultra-sensitive sensor concepts - a biologically active graphene field effect transistor (BioGrFET) and a sensor based on microelectromechanical system (BioMEMS) technology.
The new system is designed to enable point-of-care diagnostics for virtually any type of complex liquid sample in the future. Multi-parameter analysis of infectious agents and host biomarkers will support the physician in choosing the best treatment strategy after sample analysis: whether it’s sending patients home or to a hospital, initiating empirical antibiotic therapy, supportive care or taking a wait-and-see approach. This new approach could help with preventing the spread of this infectious disease and combating the persistent infection that kills nearly 600,000 people worldwide each year. The approach enables a better and more personalized treatment for patients who are already affected by the disease and is designed to also help in monitoring disease progression.
The article was written by Katja Laska and translated by Elena OMeara COMPAMED-tradefair.com
COMPAMED SUPPLIERS FORUM by DeviceMed
The PoC-ID Project
COMPAMED offers high-tech solutions for the domain of medical devices. It has become an international leading trade fair for the supplier market of medical manufacturing. The medical devices industry is one of the most dynamically growing markets. This can be seen in the constantly growing numbers of visitors at the COMPAMED/ MEDICA.
IVAM, the professional association for micro-technology, points the way to the COMPAMED HIGH-TECH FORUM by IVAM and presents technologies and solutions for the future.